Boxer Capital, LLC Uni Qure N.V. Transaction History

Boxer Capital, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$26.01 - $38.22 $6.5 Million - $9.56 Million	-250,000 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$35.35 - $50.67 $18.2 Million - $26.1 Million	-515,400 Reduced 67.34%	250,000 $9.03 Million
Q4 2019 Feb 14, 2020	SELL	$37.13 - $74.62 $3.71 Million - $7.46 Million	-100,000 Reduced 11.56%	765,400 $54.8 Million
Q3 2019 Nov 14, 2019	BUY	$39.36 - $76.8 $9.84 Million - $19.2 Million	250,000 Added 40.62%	865,400 $34.1 Million
Q2 2019 Aug 14, 2019	SELL	$52.76 - $82.19 $17.7 Million - $27.5 Million	-334,600 Reduced 35.22%	615,400 $48.1 Million
Q1 2019 May 15, 2019	SELL	$27.39 - $68.41 $6.85 Million - $17.1 Million	-250,000 Reduced 20.83%	950,000 $56.7 Million
Q4 2018 Feb 14, 2019	BUY	$22.8 - $33.93 $27.4 Million - $40.7 Million	1,200,000 New	1,200,000 $34.6 Million

141

33.7M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $237M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Boxer Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Boxer Capital, LLC with notifications on news.